🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Sakar Healthcare Limited SAKAR NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.sakarhealthcare.com
Company Profile ↓
₹930.40
+168.20% 1Y
Mkt Cap₹2,042.22 Cr
P/E117.03
P/B5.92
52W High₹930.40
52W Low₹317.10
Book Value₹147.81
EPS (TTM)₹7.95

Company Overview

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaesthetic, bronchodilator, adrenergic, sedative, anti-inflammatory, antiemetic, anticonvulsant, antipsychotic, antidepressant, and anti-cancer. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 33.7% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 23.6% CAGR over the past five years.

Healthy Margins

Operating margin of 18.0% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.17.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹251.74 Cr (+41.8% YoY); net profit ₹30.48 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +41.8%, earnings +74.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 23.6%, profit CAGR 33.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:23.59%
1 Year:41.76%

Compounded Profit Growth

5 Years:33.69%
1 Year:74.18%

Stock Price Performance

1 Year:+168.20%
6 Months:+144.78%
3 Months:+57.63%
1 Month:+10.22%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹317.10 ₹930.40
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)69.57 · Neutral
Price Performance
1M+10.22%
3M+57.63%
6M+144.78%
1Y+168.20%
Valuation vs Sector

P/E of 117.03 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 23.6% over 5 years.
  • Profit CAGR of 33.7% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 117.0.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
117.03
Industry PE
39.97
Forward P/E
25.01
PEG Ratio
-
Book Value
₹147.81
Price to Book
5.92
P/S
7.53
EV/EBITDA
28.88
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
23.59%
Profit 5Y
33.69%
Revenue (YoY)
41.76%
Earnings (YoY)
74.18%

Profitability & Returns

ROCE
12.82%
ROE
9.40%
ROA
6.34%
Profit Margin
12.11%
Op Margin
18.00%
Gross Margin
51.03%
EPS (Latest Qtr)
₹4.96
EPS (TTM)
₹7.95

Balance Sheet & Liquidity

Debt/Equity
0.17
Quick Ratio
0.64
Current Ratio
1.28
Debt
₹55.30 Cr
Total Assets
₹481.01 Cr
Current Assets
₹140.46 Cr
Working Capital
₹30.92 Cr

Ownership

Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹2,042.22 Cr
Total Revenue (TTM)
₹251.74 Cr
EBITDA
₹71.18 Cr
Free Cash Flow
₹20.91 Cr
Operating Cash Flow
₹49.26 Cr
Shares Outstanding
₹2.19 Cr
Gross Margin
51.03%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SAKAR Sakar Healthcare Limited NSEPHARMA 930.40 117.03 ₹2,042.22 Cr 0.00% 12.82% 9.40% 23.59% 33.69%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 41.00 Cr39.00 Cr34.00 Cr37.00 Cr43.00 Cr41.00 Cr--50.24 Cr52.74 Cr57.56 Cr70.34 Cr71.10 Cr
Cost of Revenue --------14.67 Cr28.95 Cr30.41 Cr35.54 Cr28.38 Cr
Gross Profit --------35.57 Cr23.78 Cr27.15 Cr34.81 Cr42.72 Cr
Operating Expenses 33.00 Cr30.00 Cr25.00 Cr28.00 Cr32.00 Cr30.00 Cr--25.32 Cr16.65 Cr21.48 Cr22.59 Cr22.42 Cr
Operating Income 4.00 Cr4.00 Cr5.00 Cr5.00 Cr6.00 Cr6.00 Cr--10.25 Cr7.13 Cr5.67 Cr12.22 Cr20.30 Cr
EBITDA 8.00 Cr9.00 Cr9.00 Cr9.00 Cr11.00 Cr11.00 Cr--15.91 Cr13.10 Cr12.57 Cr19.10 Cr26.41 Cr
Interest Expense 2.00 Cr2.00 Cr2.00 Cr2.00 Cr2.00 Cr1.00 Cr--4.19 Cr2.14 Cr1.53 Cr1.78 Cr2.41 Cr
Pretax Income 4.00 Cr4.00 Cr4.00 Cr3.00 Cr5.00 Cr5.00 Cr--6.24 Cr5.38 Cr5.36 Cr10.95 Cr18.06 Cr
Tax Provision -4.00 L1.12 Cr52.00 L93.00 L1.75 Cr2.45 Cr--47.54 L71.35 L81.81 L70.34 L7.04 Cr
Net Income 4.00 Cr3.00 Cr4.00 Cr2.00 Cr3.00 Cr2.00 Cr--5.76 Cr4.67 Cr4.54 Cr10.25 Cr11.02 Cr
Diluted EPS 2.061.491.700.951.431.11--2.652.112.034.594.96

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 83.00 Cr95.00 Cr-133.36 Cr153.35 Cr177.58 Cr251.74 Cr
Cost of Revenue ---73.79 Cr83.68 Cr82.26 Cr123.28 Cr
Gross Profit ---59.57 Cr69.67 Cr95.32 Cr128.46 Cr
Operating Expenses 63.00 Cr72.00 Cr-40.45 Cr48.52 Cr66.52 Cr83.14 Cr
Operating Income 13.00 Cr15.00 Cr-19.12 Cr21.15 Cr28.80 Cr45.32 Cr
EBITDA 20.00 Cr23.00 Cr-37.35 Cr40.70 Cr50.94 Cr71.18 Cr
Interest Expense 2.00 Cr2.00 Cr-5.49 Cr6.75 Cr8.54 Cr7.86 Cr
Pretax Income 12.00 Cr13.00 Cr-16.88 Cr15.90 Cr21.53 Cr39.76 Cr
Tax Provision 2.52 Cr2.47 Cr-4.12 Cr4.23 Cr4.03 Cr9.27 Cr
Net Income 10.00 Cr11.00 Cr-12.76 Cr11.67 Cr17.50 Cr30.48 Cr
Diluted EPS 6.436.8410.096.865.677.95-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 115.00 Cr178.00 Cr-336.34 Cr388.66 Cr415.26 Cr481.01 Cr
Current Assets ---55.92 Cr71.61 Cr88.73 Cr140.46 Cr
Cash & Equivalents ---9.33 L25.79 L10.16 L4.22 L
Inventory ---15.40 Cr27.73 Cr43.59 Cr70.04 Cr
Receivables ---22.08 Cr20.91 Cr30.72 Cr50.08 Cr
Total Liabilities ---162.99 Cr126.33 Cr129.79 Cr156.56 Cr
Current Liabilities ---54.49 Cr59.06 Cr63.19 Cr109.54 Cr
Long Term Debt ---98.23 Cr54.95 Cr53.59 Cr31.35 Cr
Total Debt 17.00 Cr43.00 Cr-119.18 Cr79.35 Cr86.37 Cr55.30 Cr
Total Equity 81.00 Cr99.00 Cr-173.35 Cr262.33 Cr285.48 Cr324.45 Cr
Shares Outstanding --1.71 Cr1.90 Cr2.17 Cr2.19 Cr-

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 19.00 Cr15.00 Cr-33.34 Cr24.47 Cr34.03 Cr49.26 Cr
Investing Cash Flow -22.00 Cr-47.00 Cr--74.38 Cr-51.54 Cr-30.71 Cr-28.35 Cr
Financing Cash Flow 3.00 Cr32.00 Cr-41.10 Cr27.44 Cr-3.48 Cr-20.96 Cr
Capital Expenditure -23.00 Cr-47.00 Cr--82.20 Cr-59.56 Cr-32.28 Cr-28.35 Cr
Free Cash Flow -4.00 Cr-32.00 Cr--48.85 Cr-35.09 Cr1.75 Cr20.91 Cr
Net Change in Cash -0-0-6.34 L37.24 L-15.62 L-4.97 L

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---44.7%45.4%53.7%51.0%
Operating Margin % 15.7%15.8%-14.3%13.8%16.2%18.0%
Net Margin % 12.0%11.6%-9.6%7.6%9.9%12.1%
ROE % 12.3%11.1%-7.4%4.4%6.1%9.4%
ROCE % ---6.8%6.4%8.2%12.2%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SAKAR

Google News hu, 09 Jul 2026

Cobra India acquires 2.05% stake in Sakar Healthcare via open market - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQTVLVG01cXVlYUhkVmgtVVIzVUFKTWV2NTVHMVZzMzZKcWtMRDRsX09FenVWSEdmRVQxWWNYdDVVZlBqMS1vWlJWVmJpRU9YVkttR291RTBaS0U5TjJNRE9aaU1XUnUydFRFcHZEVGNiWkRzUnplejdGTS0zV0xRRVFWSHQ0RVpjQ21WRj…

Google News Fri, 06 Feb 2026

Sakar Healthcare Limited's (NSE:SAKAR) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPVVUwcnZBeTVwX2RraHh0NGFpZW9ZY08xWTR5bFRPSERQS1A3ekVBRzBBRTY4SXFRZnp0SURHd1lDd3JhQ1h5RjFxdGotZVM2ZUhpcXRrQzRfcExKTEMtUVZ6cElMUWRjTmxUaUtkZ2NOUk1QT2xGaGhIdWlCYWVnUDg1UHFXWXdaWV9DSm…

Google News Sat, 16 May 2026

Stellar Wealth Partners India Fund acquires 0.87% stake in Sakar Healthcare, Zerodha Broking buys Rs 93... - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMipwJBVV95cUxOTGs0OWtJNXR2S2FKWkNHcXRHQ0dJU0pwTGxFT21yY2lCZE14U0lrQzAyeDRYc2l3V1pVOXJsLXdHclZablQ3YVJVcmhCSExOb1daMTcxZVJUbTRTbzEteFJ6X0U2UHBZUVVma0owYWpGRzkzLXJJOU9qVnM5aTlPZ3h6VFFqZUdCb09UeW…

Google News ue, 10 Feb 2026

Subdued Growth No Barrier To Sakar Healthcare Limited (NSE:SAKAR) With Shares Advancing 31% - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPMGNYUjN1MlJWSE1Sb3FDakFBZWw1N1lLdHlWeU02VF9nZ0dGMkp1RWlaRmpoekRBeE1vTWVfaVZQb0tYQmpuT09RQ1JOMU1HQ1puZDk0bnJTWG5jakxib0ZwRmxHempZaHprOVVUMkZnaGpPa0JuWUxkcGJveVlYbmVXdU5ZY0hkSXJFan…

Google News Mon, 18 May 2026

Sakar Healthcare jumps after Gautam Baid-founded fund buys stake via bulk deal - Business Standard

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNelNlR01mSDZkTUZZZGMwY3R4YUx4MFBsTjJLcGdCejBMeVFxS2FMUFVKMzFobmdJVy1vT3ViMEdWNWVCTDdQeDdyUWxSejIyakpfNGNTX0x3YWJXSmFmQUNPcER1WkR0U2hXaXZXZnIyUWdSYURiNWhnZi1Ydk5hcHpvYW8tczZYd3pNeE…

Google News hu, 06 Nov 2025

Sakar Healthcare Share Price Gains 1% on 9 New Oncology Approvals - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTFB6TFhfYUhkakttTEJIU3ZaaThWT1BIOUVmUkFhN3hTVHZYazhnaDYyYWJvQzI5ZlI4UHM2WGo0a2d3VEZiRFRST2RZX2N2aHZybFYyMkJNVHpzcExYNGdna25aR3g5b0wtbWtSbmdpbl8?oc=5" target="_blank">Sakar Healthcare…

SAKAR — Frequently Asked Questions

What is the current share price of Sakar Healthcare Limited (SAKAR)?

As of 2026-07-15 09:52 IST, Sakar Healthcare Limited (SAKAR) trades at ₹930.40 on NSE. Its 52-week range is ₹317.10 to ₹930.40.

What is the market capitalisation of SAKAR?

Sakar Healthcare Limited (SAKAR) has a market capitalisation of ₹2,042.22 Cr on NSE.

What is the P/E ratio of SAKAR?

SAKAR trades at a trailing price-to-earnings (P/E) ratio of 117.03. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.92.

What is the return on equity (ROE) of SAKAR?

SAKAR has a return on equity (ROE) of 9.40%. Its return on capital employed (ROCE) is 12.82%.

Is SAKAR a good stock to buy?

This page provides a data-driven analysis of Sakar Healthcare Limited (SAKAR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space